Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORE LABORATORIES N VCLB · Entity 11862 | CAO & Treasurer | February 16, 2023 | February 21, 2023 |
| Core Laboratories Inc. /DE/CLB · Entity 5382 | CAO & Treasurer | February 15, 2024 | February 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORE LABORATORIES N V
Report date February 16, 2023 · Filed February 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 12,240 |
Reported balance
After 2023-02-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-16 · Grant · Acquired 12,240 · Balance 12,240 F1: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance criteria set forth below, this award will vest at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). At the end of the Performance Period, 50% of the award will vest if the Company is in the top 55th percentile of Return On Invested Capital (ROIC) of the Bloomberg Peer Group (BPG), and 100% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile (equivalent to 50% up to 100% of the award). |
Filing footnotes · ownership attribution and instrument terms
F1: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance criteria set forth below, this award will vest at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). At the end of the Performance Period, 50% of the award will vest if the Company is in the top 55th percentile of Return On Invested Capital (ROIC) of the Bloomberg Peer Group (BPG), and 100% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile (equivalent to 50% up to 100% of the award).
Core Laboratories Inc. /DE/
Report date February 15, 2024 · Filed February 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 8,882 |
Reported balance
After 2024-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-15 · Grant · Acquired 8,882 · Balance 8,882 F1: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance criteria set forth below, this award will vest at the end of a three-year performance period that began on January 1, 2024 and ends on December 31, 2026 (the"Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 55th percentile of Return On Invested Capital (ROIC) of the Bloomberg Peer Group (BPG), and 200% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile (equivalent to 100% up to 200% of the award). |
Filing footnotes · ownership attribution and instrument terms
F1: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance criteria set forth below, this award will vest at the end of a three-year performance period that began on January 1, 2024 and ends on December 31, 2026 (the"Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 55th percentile of Return On Invested Capital (ROIC) of the Bloomberg Peer Group (BPG), and 200% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile (equivalent to 100% up to 200% of the award).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2024 Filed Feb 15, 2024 16:11 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | GrantPerformance Shares · Derivative | 8,882 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015887 · ownership.xml · derivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,882 Underlying: Common Stock · 8,882 shares Expires not disclosed F1 · derivative.exercise_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance criteria set forth below, this award will vest at the end of a three-year performance period that began on January 1, 2024 and ends on December 31, 2026 (the"Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 55th percentile of Return On Invested Capital (ROIC) of the Bloomberg Peer Group (BPG), and 200% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile (equivalent to 100% up to 200% of the award). F1 · derivative.expiration_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance criteria set forth below, this award will vest at the end of a three-year performance period that began on January 1, 2024 and ends on December 31, 2026 (the"Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 55th percentile of Return On Invested Capital (ROIC) of the Bloomberg Peer Group (BPG), and 200% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile (equivalent to 100% up to 200% of the award). Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 17:47 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionPerformance Shares · Derivative | 7,200 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-001245 · ownership.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These shares were awarded as restricted performance shares in February 2021, as disclosed in the Reporting Person's Form 4 filing on February 19, 2021. All requirements for 100% vesting have been met and thus the restricted shares vested on Decmeber 31, 2023 at the conclusion of the performance period. F1 · derivative.expiration_date: These shares were awarded as restricted performance shares in February 2021, as disclosed in the Reporting Person's Form 4 filing on February 19, 2021. All requirements for 100% vesting have been met and thus the restricted shares vested on Decmeber 31, 2023 at the conclusion of the performance period. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 17:47 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 7,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-001245 · ownership.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 17:47 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 2,769 | $17.66 | $48,900.54 |
DisclosureSEC source: 0000950170-24-001245 · ownership.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,180 Read SEC document |
| December 31, 2023 Filed Jan 8, 2024 14:50 UTC Amendment | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 2,834 | $17.66 | $50,048.44 |
DisclosureSEC source: 0000950170-24-002892 · ownership.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,115 F1 · shares: The original Form 4, filed on January 3, 2024, is being amended by this Form 4 amendment to correct an administrative error of the issuer, whereupon the number of shares withheld to satisfy tax withholding obligations upon vesting of certain restricted performance shares was misreported as 2,769 shares. The corrected transaction reflects an increase of 65 shares withheld by the issuer as a result such vesting and a corresponding reduction in the number of shares beneficially owned by the reporting person. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 16:51 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionRestricted Shares · Derivative | 140 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-067805 · ownership.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 16:51 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Exercise / conversionCommon Stock | 140 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-067805 · ownership.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 16:51 UTC | Core Laboratories Inc. /DE/ CLB · Entity 5382 | Tax withholdingCommon Stock | 54 | $18.07 | $975.78 |
DisclosureSEC source: 0000950170-23-067805 · ownership.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,749 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 15:15 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantPerformance Shares · Derivative | 12,240 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011095 · doc4.xml · derivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,240 Underlying: Common Shares · 12,240 shares Expires not disclosed F1 · derivative.exercise_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance criteria set forth below, this award will vest at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). At the end of the Performance Period, 50% of the award will vest if the Company is in the top 55th percentile of Return On Invested Capital (ROIC) of the Bloomberg Peer Group (BPG), and 100% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile (equivalent to 50% up to 100% of the award). F1 · derivative.expiration_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance criteria set forth below, this award will vest at the end of a three-year performance period that began on January 1, 2023 and ends on December 31, 2025 (the "Performance Period"). At the end of the Performance Period, 50% of the award will vest if the Company is in the top 55th percentile of Return On Invested Capital (ROIC) of the Bloomberg Peer Group (BPG), and 100% of the award will vest if the Company is in the top 85th percentile of ROIC of the BPG, as measured and determined by the Compensation Committee at the end of the Performance Period. The number of common shares vesting pursuant to the award will be interpolated on a straight-line basis between the 55th and 85th percentile (equivalent to 50% up to 100% of the award). Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 16:50 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionPerformance Shares · Derivative | 6,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001016 · doc4.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These shares were awarded as restricted performance shares in February 2020, as disclosed in the Reporting Person's Form 4 filing on February 12, 2020. All requirements for 100% vesting have been met and thus the restricted shares vested on December 31, 2022 at the conclusion of the performance period. F1 · derivative.expiration_date: These shares were awarded as restricted performance shares in February 2020, as disclosed in the Reporting Person's Form 4 filing on February 12, 2020. All requirements for 100% vesting have been met and thus the restricted shares vested on December 31, 2022 at the conclusion of the performance period. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 16:50 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001016 · doc4.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 16:50 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 2,361 | $20.27 | $47,857.47 |
DisclosureSEC source: 0001209191-23-001016 · doc4.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,663 Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 13:32 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 140 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-059313 · doc4.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140 Underlying: Common Shares · 140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each such vesting date F2 · balance_after: Mulitple restricted share grants are included in this total. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 13:32 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 140 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-059313 · doc4.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 13:32 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 56 | $21.50 | $1,204.00 |
DisclosureSEC source: 0001209191-22-059313 · doc4.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,024 Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 16:19 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014724 · doc4.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280 Underlying: Common Shares · 120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each vest date. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each vest date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each vest date. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 16:19 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014724 · doc4.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 16:19 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 54 | $27.51 | $1,485.54 |
DisclosureSEC source: 0001209191-22-014724 · doc4.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,940 Read SEC document |
| February 17, 2022 Filed Feb 17, 2022 17:14 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantPerformance Shares · Derivative | 9,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010886 · doc4.xml · derivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Shares · 9,500 shares Expires not disclosed F1 · derivative.exercise_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance goals is achieved, this award would vest at the end of a three-year performance period that began on January 1, 2022 and ends on December 31, 2024 (the "Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 75th percentile of Return On Invested Capital of the Bloomberg Peer Group as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance goals is achieved, this award would vest at the end of a three-year performance period that began on January 1, 2022 and ends on December 31, 2024 (the "Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 75th percentile of Return On Invested Capital of the Bloomberg Peer Group as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:52 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionPerformance Shares · Derivative | 3,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001061 · doc4.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These awards vested at the end of a three-year performance period that began on January 1, 2019 and ended December 31, 2021 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top 75th percentile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. F1 · derivative.expiration_date: These awards vested at the end of a three-year performance period that began on January 1, 2019 and ended December 31, 2021 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top 75th percentile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:52 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 3,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001061 · doc4.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 17:52 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 1,496 | $22.31 | $33,375.76 |
DisclosureSEC source: 0001209191-22-001061 · doc4.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,874 Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 10:24 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 140 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-067730 · doc4.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Underlying: Common Shares · 140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each vesting date. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each vesting date. F2 · balance_after: Multiple restricted share grants are included in this total. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 10:24 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 140 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-067730 · doc4.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 10:24 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 56 | $22.41 | $1,254.96 |
DisclosureSEC source: 0001209191-21-067730 · doc4.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,570 Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:32 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 105 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045487 · doc4.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540 Underlying: Common Shares · 105 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each vesting date. F1 · derivative.exercise_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each vesting date. F1 · derivative.expiration_date: The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount of 1/6th of the grant total, provided the reporting person remains in continuous service on each vesting date. F2 · balance_after: Mulitple restricted share grants are included in this total. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:32 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 48 | $39.11 | $1,877.28 |
DisclosureSEC source: 0001209191-21-045487 · doc4.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,486 Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:32 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 105 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045487 · doc4.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 17:39 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 120 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016352 · doc4.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 645 Underlying: Common Shares · 120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · balance_after: Mulitple restricted share grants are included in this total. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 17:39 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 55 | $36.84 | $2,026.20 |
DisclosureSEC source: 0001209191-21-016352 · doc4.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,429 Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 17:39 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016352 · doc4.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 16:55 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantPerformance Shares · Derivative | 7,200 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013264 · doc4.xml · derivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,200 Underlying: Common Shares · 7,200 shares Expires not disclosed F1 · derivative.exercise_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance goals is achieved, this award would vest at the end of a three-year performance period that began on January 1, 2021 and ends on December 31, 2023 (the "Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 75th percentile of Return On Invested Capital of the Bloomberg Peer Group as measured and determined by the Compensation Committee at the end of the Performance Period. F1 · derivative.expiration_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance goals is achieved, this award would vest at the end of a three-year performance period that began on January 1, 2021 and ends on December 31, 2023 (the "Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 75th percentile of Return On Invested Capital of the Bloomberg Peer Group as measured and determined by the Compensation Committee at the end of the Performance Period. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 16:21 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionPerformance Shares · Derivative | 2,600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001053 · doc4.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These awards vested at the end of a three-year performance period that began on January 1, 2018 and ended December 31, 2020 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top 75th percentile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. F1 · derivative.expiration_date: These awards vested at the end of a three-year performance period that began on January 1, 2018 and ended December 31, 2020 (the "Performance Period"). The restricted performance shares would vest only upon the Company's return on invested capital being in the top 75th percentile of the Company's peers as published by Bloomberg upon the close of the NYSE market on the last day of the Performance Period. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 16:21 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 1,024 | $26.51 | $27,146.24 |
DisclosureSEC source: 0001209191-21-001053 · doc4.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,364 Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 16:21 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001053 · doc4.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 11:32 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 140 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-061035 · doc4.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765 Underlying: Common Shares · 140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · balance_after: Mulitple restricted share grants are included in this total. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 11:32 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 54 | $23.20 | $1,252.80 |
DisclosureSEC source: 0001209191-20-061035 · doc4.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788 Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 11:32 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 140 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-061035 · doc4.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 16:06 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 105 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-040231 · doc4.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 905 Underlying: Common Shares · 105 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · balance_after: Mulitple restricted share grants are included in this total. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 16:06 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 47 | $20.35 | $956.45 |
DisclosureSEC source: 0001209191-20-040231 · doc4.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 702 Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 16:06 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 105 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-040231 · doc4.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 14:54 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 70 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022440 · doc4.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,010 Underlying: Common Shares · 70 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · balance_after: Mulitple restricted share grants are included in this total. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 14:54 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 32 | $9.49 | $303.68 |
DisclosureSEC source: 0001209191-20-022440 · doc4.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644 Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 14:54 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 70 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022440 · doc4.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 16:12 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 120 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015113 · doc4.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,080 Underlying: Common Shares · 120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · balance_after: Mulitple restricted share grants are included in this total. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 16:12 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 54 | $26.84 | $1,449.36 |
DisclosureSEC source: 0001209191-20-015113 · doc4.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606 Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 16:12 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionCommon Shares | 120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015113 · doc4.xml · nonDerivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 17:19 UTC | CORE LABORATORIES N V CLB · Entity 11862 | GrantPerformance Shares · Derivative | 6,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-008881 · doc4.xml · derivative · entry 1 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Shares · 6,000 shares Expires not disclosed F1 · derivative.exercise_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance goals is achieved, this award would vest at the end of a three-year performance period that began on January 1, 2020 and ends on December 31, 2022 (the "Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 75th percentile of Return On Invested Capital of the Bloomberg Peer Group as shown by data published by Bloomberg upon the close of the NYSE market on the last trading day of the Performance Period. If this criteria is not met, then no shares shall vest and the award shall be forfeited. F1 · derivative.expiration_date: Assuming a recipient's continued employment (or death or disability while employed) and the satisfaction of certain performance goals is achieved, this award would vest at the end of a three-year performance period that began on January 1, 2020 and ends on December 31, 2022 (the "Performance Period"). At the end of the Performance Period, 100% of the award will vest if the Company is in the top 75th percentile of Return On Invested Capital of the Bloomberg Peer Group as shown by data published by Bloomberg upon the close of the NYSE market on the last trading day of the Performance Period. If this criteria is not met, then no shares shall vest and the award shall be forfeited. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 15:00 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Exercise / conversionRestricted Shares · Derivative | 140 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-058662 · doc4.xml · derivative · entry 3 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Shares · 140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F1 · derivative.expiration_date: The Restricted Shares vest in the amount of 1/6th of the grant on each of the six annual anniversaries following the date of grant. F2 · balance_after: Mulitple restricted share grants are included in this total. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 15:00 UTC | CORE LABORATORIES N V CLB · Entity 11862 | Tax withholdingCommon Shares | 54 | $43.80 | $2,365.20 |
DisclosureSEC source: 0001209191-19-058662 · doc4.xml · nonDerivative · entry 2 Daniels Kevin · CIK 0001740507 · CAO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.